Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan Pharmaceuticals, subsidiary of Mylan Inc, has won the US Food and Drug Administration approval for its abbreviated new drug application (ANDA) of Nisoldipine extended-release (ER) tablets, 8.5mg, 17mg, 25.5mg and 34mg.
Subscribe to our email newsletter
Mylan Pharma clams that Nisoldipne ER tablets are the generic version of Shiongi Pharma’s hypertension treatment, Sular.
Sular (nisoldipine), Nisoldipine is in a group of drugs called calcium channel blockers which relaxes (widens) blood vessels and improves blood flow.
Nisoldipine is used to treat high blood pressure (hypertension).